Molecule Structure

Scientific Name

Imatinib

Description of the Drug

Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-02-07 from
http://www.drugbank.ca/drugs/DB00619

Brand Name(s)

Not Available

Company Owner(s)

Mylan Pharmaceuticals Inc, Hikma Pharmaceuticals Usa Inc, Teva Pharmaceuticals Usa, Natco Pharma Ltd, Novartis Pharmaceuticals Corp, Dr Reddys Laboratories Ltd, Apotex Inc, Amneal Pharmaceuticals Of New York Llc, Wockhardt Bio Ag, Sun Pharmaceutical Industries Ltd

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
Bcr/Abl fusion protein CHIMERIC PROTEIN INHIBITOR CHEMBL2096618
Platelet-derived growth factor receptor beta SINGLE PROTEIN INHIBITOR CHEMBL1913
Tyrosine-protein kinase ABL SINGLE PROTEIN INHIBITOR CHEMBL1862
Stem cell growth factor receptor SINGLE PROTEIN INHIBITOR CHEMBL1936

Unichem Links

Atlas imatinib
SureChEMBL SCHEMBL3827
PharmGKB PA10804
Human Metabolome Database HMDB0014757
WDI DR9601648 DR9712313
DrugBank DB00619
PubChem: Thomson Pharma 14859628
PubChem 5291
Mcule MCULE-2384256888
LINCS LSM-1023
Nikkaji J1.337.143A
PDBe STI
NCC 5101
BindingDB 13530
EPA CompTox Dashboard DTXSID3037125
DrugCentral 1423
Brenda 229530 2314 229529 163324
ChemicalBook CB7370890
Guide to Pharmacology 5687
GSRS 9fdb59f1-dd06-450e-b973-014d7d4bb468
rxnorm IMATINIB GLEEVEC IMATINIB MESYLATE
ChEBI 45783
ZINC ZINC000019632618